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ABSTRACT 
Introduction: Psoriasis is a chronic inflammatory skin disease affecting 2–3% of the population. 
Certain systemic drugs currently available for its treatment could be associated, in the long term, 
with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. 
Moreover, tolerability issues, parenteral administration, and barriers to patient access, such as high 
cost and specialist management lead to treatment failure.  
Areas covered: Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4i). PDE 
is the major enzyme class responsible for the hydrolysis of cyclic adenosine monophosphate in 
immune cells (cAMP). With PDE4 inhibition, apremilast works intracellularly to modulate pro-
inflammatory and anti-inflammatory mediator production critically involved in psoriasis. 
The aim of this paper is to focus the attention on apremilast pharmacodynamics effects, its efficacy 
and safety in treating moderate-to-severe plaque psoriasis. 
Expert opinion: Apremilast is an effective and well-tolerated option in treating moderate-to-severe 
plaque psoriasis. Its safety profile and the oral administration offer significant advantages in 
prescribing apremilast for the treatment of psoriasis, particularly in some subsets of patients.  
 
KEYWORDS:  Apremilast, phosphodiesterase-4-inhibitor, psoriasis, oral therapy, small molecule. 
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Box 1. Drug summary 
Drug name Apremilast 
Phase: EMA approval January 2015. for the 
treatment of adults with 
moderate-to-severe 
plaque psoriasis and 
psoriasic arthritis  
 
Indication Psoriasis; Psoriasic arthritis 
Pharmacology 
description/mechanism 
of action 
cAMP PDE4 inhibitor 
Route of administration Oral 
Chemical structure C22H24N2O7S 
 
Pivotal trial(s) 
ESTEEM 1 and ESTEEM 2
[5,44] 
 
adverse events (AEs); arthropathic psoriasis (PsA); bis in die (b.i.d.); Body Surface Area 
(BSA); Cyclic adenosine monophosphate (cAMP); cAMP responsive element binding protein 
(CREB); Exchange protein directly activated by cAMP 1 (Epac1); inducible NO synthase 
(iNOS); Janus kinase (JAK); Lipopolysaccharide (LPS); Mieloid Dendritic Cells (mDC); 
NAPSI (Nail Psoriasis Severity Index); Natural Killer (NK); Nuclear factor-κB (NF-κB); 
Peripheral blood mononuclear cells (PBMCs); Plasmacytoid Dendritic Cells  (pDCs); 
Phosphodiesterases (PDEs); Phosphodiesterase 4 (PDE4); Physician's Global 
Assessment (sPGA); PDE4 inhibitors (PDE4i);  Protein Kinase A (PKA); Psoriasis Area 
Severity Index (PASI); Physician global assessment for lesions of the scalp (ScPGA); Signal 
transducer and activator of transcripton (STAT); Suppressor of cytokine signaling 3 (SOCS-3); 
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1.INTRODUCTION 
Psoriasis is a chronic, inflammatory skin disease, clinically characterized by erythematous and scaly 
plaques [1]. It affects approximately 2–3 % of the population worldwide. Although the pathogenesis 
is yet to be fully elucidated, psoriasis is associated with various genetic, immunological, 
psychological and environmental factors resulting in skin inflammation and keratinocyte 
proliferation [2,3]. Psoriatic skin lesions are characterized by hyperproliferation, aberrant 
differentiation and inflammation, with the psoriatic cytokine network maintained by the crosstalk 
between immune cells and keratinocytes. In normal skin, this acute inflammatory response 
signaling is typically down-regulated by negative feedback loops maintaining the homeostatic 
function of the skin immune system  [4]. These feedbacks are altered in psoriatic patients resulting 
in chronic imbalance of pro- and anti-inflammatory cytokines [5]. 
The earliest trigger event seems to be the recruitment of plasmacytoid dendritic cells  (pDCs) 
activated in response to several extracellular self-DNA fragments that get coupled to the 
endogenous cationic antimicrobial peptides such as LL-37, beta-defensin (hBD)2, hBD3, and 
lysozyme that are overexpressed in psoriatic skin. The aggregated and condensed structures formed 
by these peptides and self-DNA breaks innate tolerance via TLR9 activation which leads to IFN-α 
induction [6].  
LL-37 could also be bound to self-RNA. This compound may activate pDCs through TLR8. 
Additionally, mDCs could also be activated directly through TLRs. LL-37 is also recognized as 
non-self antigen by autoreactive T cells. Alternatively, both pDCs and mDCs could be activated by 
chemerin, through chemr 23 receptor. IL-26 is a Th17 product that acts as antimicrobial peptide and 
bound to self DNA it activates TLR9 [7]. 
The increased concentration of IFN-α produced by activated pDCs stimulates mDCs and T cells to 
secrete several inflammatory and proliferative mediators (i.e., TNF-α, IL-23, IL-22, IL-21, IL-6, IL-
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17, IL-20) that further promote the pathologic inflammatory cascade [8]. T cells proliferate and 
differentiate into different T cells subsets, particularly into IL-17-producing T cells [9]. The 
inflammatory cascade triggers tissue cell response leading to the activation of keratinocytes, 
fibroblasts, and endothelial cells [10,11]. The microenvironment within the psoriatic plaque is 
characterized by an elevated expression of pro-inflammatory and pro-proliferative mediators 
including cytokines and chemokines that create peculiar inflammatory circuits, which might be 
therapeutically inhibited, either neutralizing these mediators (i.e., TNF-α, IL-23, and IL-17) or 
inhibiting intracellular activating signals transduced by PDE4, for instance.  
Blocking intracellular transducers that are highly expressed in activated inflammatory cells, such as 
PDE4 and janus kinase (JAK)-signal transducer and activator of transcription (STAT), it would be 
possible to inhibit a broader number of cells compared to biologic agents that target a single pro-
inflammatory mediator (i.e., TNF-α). Potentially, interrupting the inflammatory cascade at multiple 
steps including the earliest phases, could be an effective modulation of the inflammatory gene 
expression. 
 
2. OVERVIEW OF THE MARKET  
Various topical medications, phototherapy, and systemic drugs are available to treat patients with 
psoriasis of varying disease severity.  
The current gold standard is represented by biologic therapies targeting TNF-α and IL-12/23, which 
have dramatically improved clinical outcomes in patients with psoriasis.  Despite the large number 
of drugs available, patients with psoriasis are often dissatisfied with those treatments.  
Few studies estimated how many patients receive adequate treatments and fewer data is available 
about patients’ satisfaction. Emerging data shows that a large proportion of patients with psoriasis 
are not receiving any treatment and almost 30% of patients with moderate-to-severe psoriasis are 
undertreated, receiving topical medication only [12].  Moreover, there are patients either non-
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responding to currently available biological agents or have experienced diminishing therapeutic 
benefit over time [13, 14].  
Although adverse effects and lack of effectiveness are primary reasons for discontinuing biological 
agents, route of administration, inability to reach specialized centers to obtain adequate assistance 
are mentioned among the top reasons for discontinuation. Thus, in spite of a range of options, 
effective treatment of psoriasis can be challenging. For this reason other new frontiers of medical 
and pharmaceutical research are explored to elucidate the immunopathogenesis of psoriasis and 
attempt to develop new therapeutic agents against different molecular pathways. In this landscape, 
small molecules including JAK and PDE4 inhibitors (PDE4i) could represent promising therapeutic 
targets for moderate-to-severe psoriasis.  
 
3. INTRODUCTION TO THE COMPOUND 
During the inflammatory process immune cells belonging to both innate and adaptive immunity are 
stimulated to produce pro-inflammatory and pro-proliferative mediators, which in turn, induce the 
activation of tissue cells, especially keratinocytes, fibroblasts and endothelial cells that participate to 
skin inflammation at lesional sites, secreting pro-inflammatory mediators and sustaining immune 
cell recruitment [15]. Both immune and tissue cells share a common key transducer for pro-
inflammatory intracellular signaling, represented by the intracellular concentration of cAMP. cAMP  
is a second messenger involved in numerous cellular functions, including modulation of cytokine 
production in immune cells [16]. It plays a critical role in transducing extracellular stimuli into 
intracellular signals,  and, thus, in controlling gene expression [17]. 
The inflammatory milieu induces G-protein-coupled receptors to bind and activate adenylyl cyclase, 
which determines increased production of cAMP [18]. High intracellular levels of cAMP increase 
anti-inflammatory cytokine production via activation of protein kinase A (PKA) and subsequent 
phosphorylation of transcription factors including CREB (cAMP responsive element binding 
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protein) which is a transcription factor capable of transcribing anti-inflammatory cytokine genes 
and ATF1 (activating transcription factor-1) [18, 19]. PKA activates CREB by phosphorylation as a 
result of high intracellular cAMP levels. On the other hand PKA activation leads to inhibition of 
other transcription factors like NF-κB [20, 21]. Nuclear factor-κB (NF-κB) is a transcription factor 
that contributes to the expression of proinflammatory cytokines, including TNF-α [10]. It is 
activated in response to low levels of intracellular cAMP due to decreased competition with CREB 
for transcriptional factor co-activators [22]. 
To summarize, increased level of inflammatory signals are related to low cAMP concentration and 
vice versa. This has been studied in vitro showing that stimulation of PKA by selective cAMP-
derived agonists, decrease pro-inflammatory cytokine production from dendritic cells [23]. In most 
of the immune cell types, including those contributing to psoriasis pathogenesis, intracellular levels 
of cAMP are tightly controlled by cyclic nucleotide phosphodiesterases (PDEs), which are the only 
means of degrading cAMP, via enzymatic hydrolysis  [22]. There are 11 known subtypes of PDEs 
that play a key role in degrading cyclic nucleotides (cAMP, cGMP), which are second messengers 
in intracellular signaling [24].  
 
4.  CHEMISTRY 
Apremilast -(S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3 
dihydro-1H-isoindol-4-yl}acetamide- is an orally available PDE4 inhibitor and non-selective for 
PDE4 subtypes. With the exception of PDE4, apremilast did not significantly inhibit any of the 
kinases tested and had no significant activity against any of the cell surface receptors or enzymes 
tested [22]. Apremilast selectively binds and inhibits PDE4 through the dialkoxyphenyl 
pharmacophore [25]. This group is shared among several other PDE4i, which have been clinically 
tested or approved [26, 27].  
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5. PHARMACODYNAMIC ASSESSMENT 
Apremilast modulates immune cell activation as PDE4 inhibition reduces the production of pro-
inflammatory mediators like TNF-α, IFN-γ, IL-12/23p40, IL-23p19, IL-17A, and IL-22. On the 
other hand, apremilast has been reported to increase the production of IL-6, which shows both pro- 
and anti-inflammatory features [20, 2828]. Increasing intracellular cAMP levels, apremilast up-
regulates CREB and down-regulates NF-κB-related genes [29]. It has been shown that apremilast 
influences the expression of both innate and adaptive immune cells modulating their 
proinflammatory cytokine production, including TNF-α [30] (fig.1). 
Apremilast pharmacodynamics was assessed in several studies. In early-stage and placebo-
controlled studies in subjects with psoriasis, apremilast modulates the expression of inflammatory 
mediators, as well as demonstrated significant therapeutic activity, and an acceptable tolerability 
profile. It was estimated an epidermal thickness reduction by a mean of 20.5% from baseline at day 
29, using apremilast 20 mg QD [31]. Among responders (subjects with at least 20% reduction in 
epidermal thickness) T cells were reduced by 28.8% in the dermis and 42.6% in the epidermis. Skin 
biopsies showed a reduction in the expression of inducible NO synthase (iNOS) mRNA after 2 or 4 
weeks of treatment with apremilast. Similarly, in subjects with moderate to severe psoriasis, 
apremilast reduces keratinocyte responses to inflammation by the reduction in epidermal thickness 
[31]. 
Evaluating the effects of apremilast on LPS-stimulated human peripheral blood mononuclear cells 
(PBMCs), Schafer et al detected an attenuated expression of LPS-induced proinflammatory 
cytokines, including TNF-α, IFN-γ, IL-12A and IL-23A with apremilast treatment [32]. Apremilast 
inhibited expression of genes involved in immune-mediated pathways, including TNF-α, IFN-γ, IL-
12A and IL-23A signaling [32]. Notably, also Natural Killer (NK)-derived TNF-α production was 
inhibited by apremilast. Moreover apremilast may also suppress cytokine signaling through: the 
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activation of exchange protein directly activated by cAMP 1 (Epac1), the expression of suppressor 
of cytokine signaling 3 (SOCS-3), and the inhibition of JAK-STAT signaling [33].  
An open-label phase II study in recalcitrant psoriasis reported that apremilast suppresses MX1 
mRNA expression (marker of the type 1 IFNs response in skin lesions) and reduces IFN-α secretion 
by activated pDCs [34]. 
Overall, apremilast seems to act mainly on the innate immune cell compartment (i.e., neutrophils, 
and NK cells) and, to a lesser extent, on adaptive immune cells. In particular, apremilast  does not 
affect in vivo B-cell activation, as detected in an antigen-specific mouse B-cell transfer model [32]. 
Similarly, PDE4 inhibition has no significant effects on keratinocyte proliferation, as well as 
keratinocyte-derived TNF-α production. Thereby, the reduced cytokine expression derived from the 
adaptive immune compartment as well as the suppression of keratinocyte proliferation, seems to 
represent the downstream result of apremilast activity on innate immune cells that are primarily 
involved in the early stages of psoriasis pathogenesis [32,35]. 
Pharmacodynamic effects of apremilast on plasma biomarkers have been investigated in a phase III 
substudy, within the PALACE I study, correlating the decrease of inflammatory biomarkers with 
the clinical improvement in three groups of patients (20 mg b.i.d, 30 mg b.i.d., and placebo). 
Although PALACE I assessed apremilast efficacy in psoriatic arthritis, it provided relevant 
information regarding the plasma cytokine profile in response to apremilast. The pharmacodynamic 
assessment was evaluated on a panel of 47 inflammatory proteins. In both 20 mg and 30 mg arms of 
the study, after 16 and 24 weeks of treatment, significant differences of TNF-ߙ, IL-8, IL-6, ferritin, 
MIP-1ߚ, and MCP-1 serum concentrations were observed. Similarly, plasma concentrations of IL-
6, IL-17, and IL-2 were decreased by both apremilast doses, after 40-week treatment, suggesting a 
long-term inhibition of the Th-17-driven inflammation. Notably, together with the reduced plasma 
concentration of pro-inflammatory products, apremilast was associated with a significant increase in 
anti-inflammatory mediator production, namely IL-10 and IL-1RA [36].  These outcomes are in line 
with another study showing the reduced expression of  pro-inflammatory genes, namely 12/IL-
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23p40, IL-17A, and IL-23p19, in lesional skin [34]. The evidence implicates that apremilast has a 
significant impact on the IL-17 pathway, both systemically (serum level) and locally (lesional skin). 
Since, in psoriatic disease, IL-17 is produced not only by T helper cells, but also neutrophils, mast 
cells, ߛߜ T cells, and innate lymphoid cells, it could be speculated that apremilast treatment may 
modulate the activity of several immune cells that, producing IL-17, contribute to the psoriatic 
inflammatory cascade [37]. 
 
6.  PHARMACOKINETICS AND METABOLISM 
Absorption: apremilast, orally administered, is absorbed with an absolute bioavailability of ~73%, 
with peak plasma concentrations (Cmax) occurring at a median time (tmax) of ~2.5 hours. Co-
administration with food does not alter the extent of absorption of apremilast.  
Distribution: Human plasma protein rate binding to apremilast, is approximately 68%. Mean 
apparent volume of distribution (Vd) is 87 liters.  
Metabolism: After oral administration, apremilast is the major circulating component (45%) 
followed by its inactive metabolite M12 (39%). In humans, twenty-three apremilast metabolites 
have been identified and detected in plasma, urine and feces. Both cytochrome (CYP) oxidative 
metabolism, with subsequent glucuronidation, and non-CYP mediated hydrolysis metabolize 
apremilast. In vitro, CYP metabolism of apremilast is primarily mediated by CYP3A4, with minor 
contribution from CYP1A2 and CYP2A6 [38,39].  
Elimination: The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a half-life 
of approximately 6-9 hours. About 58% and 39%  is recovered in urine and feces, respectively [40]. 
Recommended dosage of apremilast is 30 mg b.i.d. approximately every 12 h with no food 
restriction. The dose should be reduced in patients with severe renal function impairment but no 
adjustment are needed for patients with hepatic disorders [41]. 
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7.  CLINICAL EFFICACY 
7.1 Phase II studies 
Clinical efficacy and safety of apremilast for the treatment of severe plaque-type psoriasis were 
firstly assessed by a phase II, multicenter, open-label, single-arm pilot study testing apremilast 20 
mg b.i.d. [31] (Tab.1). This study consisted of three phases: screening, treatment and observational 
follow-up phase (28 days, 29 days and 28 days respectively). In a phase II, open-label multicenter 
study, Gottlieb et al. [34] evaluated the efficacy, tolerability and pharmacodynamics of apremilast 
in patients with recalcitrant plaque psoriasis. The study comprised four phases and each one showed 
a improvement in BSA and in static PGA. Pharmacodynamic assessment showed a significant 
reduction of the inflammatory infiltrate localized into the dermis and epidermis, mainly constituted 
by T cells, mDCs, and NK cells  [37]. Papp et al. conducted a phase IIb, double-blind, placebo-
controlled (in the first 16 weeks), randomized, dose-ranging study evaluating different apremilast 
dosages (10, 20 and 30 mg b.i.d.) for 24 weeks, with primary endpoint designed at Week 16. 
Although a dose response was demonstrated ranging from 10 to 30 mg b.i.d, 30 mg b.i.d. resulted 
the best performing dose and it was selected for phase III studies. Conversely to the 20 mg and 30 
mg b.i.d. arms, apremilast 10 mg b.i.d. treatment did not obtain a higher response compared with 
placebo [42]. Currently, two more phase II studies in psoriasis are ongoing [43].  
 
7.2 Phase III studies: 
The efficacy and safety of apremilast have been widely evaluated in ESTEEM 1 and 2 studies. 
ESTEEM 1 and 2 are Phase III randomized studies testing apremilast 30 mg b.i.d. versus placebo in 
patients ≥18 years of age, with a ≥12 month history of chronic plaque psoriasis, who were 
candidates for treatment with phototherapy and/or systemic therapies. Additional including criteria 
were represented by: PASI score ≥12; BSA involvement ≥10%; and sPGA score of ≥3 [44, 5] 
(Tab2).  
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Efficacy data, reported in ESTEEM 1 and 2, showed an improvement in all clinical parameters in 
patients treated with apremilast. In addition to its clinical efficacy, the overall rate of side effects 
was modest. The most commonly occurring adverse events (AEs) associated with apremilast were 
diarrhea, nausea, vomiting, headache and upper respiratory infections. These AEs were dose-
dependent, mild or moderate, typically occurred in the first 14 days after starting apremilast, and 
generally resolved within 30 days without withdrawing treatment. Except for the most common 
AEs, no adverse events of special interest were observed [47] (Tab3). 
The benefits brought by apremilast in the huge panorama of psoriasis therapies is above all in terms 
of safety: no dose adjustment is necessary in contrast with the conventional medications such as 
methotrexate or cyclosporine no apremilast-treated patients had TB reactivation, nor worsening of 
heart failure, no dose adjustment are needed for those subjects with moderate and severe hepatic 
impairment.  Moreover, long-term studies conducted in mice and rats showed no increased risk of 
apremilast-induced tumors at oral doses up to 8.8 times the maximum recommended human dose 
[48]. In the latest years, long-term analysis over a 3.5-year- (182-week) period from ESTEEM 1 and 
2 trials have been presented. The ESTEEM trials safety analysis was gathered from 1.184 patients 
treated with Apremilast 30mg b.i.d. for up to 182 weeks. The pooled data showed no new safety 
signals identified, no increase in exposure-adjusted incidence rates (EAIR) of adverse events, 
serious adverse events or drug discontinuations [49]. These results were in line with previous safety 
analyses on a 2-year period (104 weeks) of apremilast treatment [50-51]. 
 
8.  REGULATORY AFFAIRS 
Apremilast was approved by the FDA at the dosage of 30 mg b.i.d for the treatment of adult patients 
with active PsA in March 2014 and recently, in September 2014, for the treatment of adult patients 
affected by moderate-to-severe plaque psoriasis who may be eligible for phototherapy or systemic 
therapy. In January 2015 apremilast was approved by the EMA for both treatments of by moderate-
to-severe plaque psoriasis and psoriatic arthritis. Clinical trial are ongoing in order to evaluate the 
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efficacy of apremilast in other autoimmune and auto-inflammatory diseases such as rheumatoid 
arthritis, dermatomyositis, Behc¸et disease, uveitis, ulcerative colitis, acute gout, erosive hand 
osteoarthritis and other cutaneous 
diseases, including atopic dermatitis, acne, rosacea and contact dermatitis (Tab 4) [43]. 
 
9.  CONCLUSION 
Despite the impressive advancement in treating psoriasis over the past 15 years, there is still need 
for further improvement. Biologicals and DMARDs have several disadvantages in term of route of 
administrations and side effects. Moreover, biologicals show increased risks for infections and 
tumors. Consistent data has demonstrated that apremilast could represent an effective and safe 
therapeutic tool for the treatment for psoriasis [52]. The value that apremilast adds to the wide 
panorama of available drugs is represented by the satisfying management of the disease without 
incurring in severe side effects, the easier route of administration and the opportunity of an effective 
therapeutic option for those patients unresponsive to both other conventional and biological agents 
or whose treatment were contraindicated [53,54].  
In September  2014, apremilast was approved by the U.S. Food and Drug Administration (FDA) for 
the treatment of patients with moderate to severe plaque psoriasis who are candidates for 
phototherapy or systemic therapy, and for the treatment of adult patients with active psoriatic 
arthritis. 
 
10. EXPERT OPINION 
Results from the aforementioned studies show that apremilast inhibits the production of multiple 
cytokines and chemokines in LPS-stimulated PBMCs such as IFN-γ, MIG, TNF-α, IL-12p70, MIP-
1α, MCP-1 and GM-CSF, but not IL-8, IL-1β, promoting the increase of IL-6. The greatest potency 
was observed against the IFN-dependent chemokines IP-10 and MIG, and IFN-γ itself, suggesting a 
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general selectivity for the interferon responsive genes [55]. Based on the current pathogenic model 
that identifies the IL-23/IL-17 axis as the main pathway driving the psoriatic plaque formation, 
apremilast effects on IL-23- and IL-17- producing cells should be more deeply investigated [56,57]. 
Acting on plasmacytoid and myeloid dendritic cells, apremilast seems to interfere with the upstream 
steps of the IL-23/IL-17 axis, but it would be interesting to define apremilast ability in directly 
inhibiting IL-17 production.   
The pharmacodynamic interaction of apremilast with the immune system cells lead to a broad, but 
not complete, inhibition of multiple pro-inflammatory mediators:  polymorphonuclear leukocytes, 
mainly neutrophils, were blocked in vitro by apremilast, including the production of IL-8 and 
LTB4 by polymorphonuclear cells as previously reported for other PDE4 inhibitors [58]. In purified 
human NK cells, apremilast inhibited production of TNF-α and GM-CSF, and IFN-γ, induced by 
IL-2 and Fc receptor (FcRγ) cross-linking. Supernatants from psoriatic NK cells have been shown 
to produce large amounts of IFN-γ, and to induce expression of ICAM-1 and MHC class II in 
psoriatic keratinocytes [59].  
Therapeutically, apremilast represent a promising option as it is well-tolerated and no blood test or 
imaging exam is mandatory during treatment. Another important advantage of apremilast is the 
route of administration and the possibility to be self-administered, the short half-life also makes 
apremilast convenient in case of sudden treatment interruption due, for example, to pregnancy or 
before major surgical intervention [60]. Nevertheless, no data o clinical reports are available 
regarding safety of apremilast during pregnancy and it is currently labeled as pregnancy category C 
drug.  
Because of the effectiveness in modulating the inflammatory cascade in adaptive and innate 
immune system and the pharmacokinetic advantages, apremilast may offers an oral treatment option 
for those patients who discontinue treatments because of ineffectiveness, intolerability, or 
ineligibility to the currently available drugs. 
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According with the current armamentarium for the treatment of psoriasis and the efficacy profile, 
apremilast could be recommended for biologic-naïve patients and in subjects who are 
contraindicated for any conventional systemic or biologic therapy. Clinical and therapeutic aspects 
related to the apremilast use still need to be investigated: for instance, its benefits in childhood and 
adolescence psoriasis. The favorable safety profile leads to consider this drug a possible therapeutic 
option that could ease the management of these patients. No clinical studies testing apremilast in 
<18 year-old patients have been performed yet, but, recently, a case of successful treatment with 
apremilast in a adolescent psoriatic patient has been described, highlighting the noticeable and 
progressive improvement of the skin lesions and his quality of life associated with a satisfactory 
safety profile [61].  
However, to place apremilast in the psoriasis therapeutic algorithm, head-to-head trials testing 
apremilast versus other therapeutics are necessary. 
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Figure 1: Mode of action of apremilast: 
Apremilast specifically inhibits PDE4. Since PDE4 degrades cAMP to AMP, intracellular levels of 
cAMP increases during apremilast administration. This results in PKA activation and 
phosphorylation of transcription factors like CREB and ATF-1 and, conversely, in inhibition of NF-
?B. This transcriptional regulation is responsible for the reduced production of pro-inflammatory 
mediators and the increased production of IL-6 and the anti-inflammatory mediator IL-10. 
 
  
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 C
hir
ico
zz
i] 
at 
11
:21
 04
 Ju
ly 
20
16
 
26 
 
Table 1 : Clinical results in the pivot phase II study CC-10004- PSOR-001 [31] 
 
  
 
An open label, single-arm pilot study in patients with severe plaque-type 
psoriasis treated with an oral anti-inflammatory agent, apremilast [31] 
CC-10004- PSOR-001 
 N° Patients  19 (17 compleeted the study and received apremilast 10mg b.i.d.)  
Baseline Characteristic (Mean) Apremilast 20 mg  Age 40.8, Sex: 84.2%  Male, Female,  15.8, PASI 18.6, BSA 30.5%  
PASI improvement  day 29: 73.7% 
PASI 50  day 29: 17.6% 
sPGA improvement day  29: 52.9%  
Epidermal quantitative total T cell count day  29: –18.6%  
Dermal quantitative total T cell count day  29: –23.4% 
epidermal thickness day  29: -20% (achieved by 53.3%) 
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Table 2 :  Clinical results in Phase III studies ESTEEMI and ESTEEMII [44, 5]. 
ESTEEM I [44] ESTEEM II [5] 
N° Patients  844 (1:2 placebo vs apremilast)  413 (1:2 placebo vs apremilast)  
Baseline Characteristic 
(Mean) Apremilast 30 
mg  
Age 45.8, Sex 67.4% Males, BMI 
31.2, PASI 18.7, BSA 24.4% VAS 
score pruritus 66.1, DLQI 12.7; 
ScPGA score ≥3 66.5%  NAPSI 
score 4.2 
Age 45.3, Sex: 64.2%  Males, BMI 
30.9, PASI 17.9, BSA 25.5% VAS score 
pruritus 67.7, DLQI 12.6; ScPGA score 
≥3 64.2%  NAPSI score 4.2  
PASI 75  
16 weeks: 33.1% vs 5.3%  
32 w 28.3%  
16w: 28.8% vs 5,8% 
32w: 24.8%  
PASI 50  
16 w: 58,7% vs 17% 
32 w : 53.6 
16w: 55.5%  vs 19.7% 
32 w: 60%  
Nail: NAPSI 50  
16 w: 33.3% vs 14.9% 
32w : 45.2 % 
52 w: 70.7%  
16w: 44.6% vs 18.7% 
32w : 55.4% 
52w:  68.6%  
Palms and soles: PPPGA 
0-1  
16w. 38.6 vs 30.8% 
32w: 42.1%  
16w: 65.4 % vs 31.3% 
32w: 53.8%  
Pruritus: VAS SCORE 
mm  
16 w: -31.5 vs -7.3 
32w: -34.5  
16w: -33.5 vs -12.2 
32w: -34.7  
QoL: DLQI 
16 w: -6.6 vs -2.1 
32w: -7.3  
16w: -6.7 vs -2.8  
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Table 3 : Summary of adverse events in Phase III clinical trials on psoriasis and/or psoriatic arthritis  
[36], [51], [44]. The frequence is defined as: very common(≥1/10); common (≥ 1/100, < 1/10); 
uncommon (≥ 1/10.000, < 1/1.000) 
 
 
  
Organs and systems Frequency Adverse event 
Infections and infestations common Bronchitis 
Upper respiratory infections 
Nasopharyngitis 
Immune system disorders uncommon Hypersensitivity 
Psychiatric disorders  Insomnia 
 
 Gastrointestinal disorders 
very common Nausea 
Diarrhea 
common Vomiting 
Dyspepsia 
Upper abdomen pain 
Weight loss 
GERD 
Frequant bowel movements 
Nervous and   
musculoskeletal system disorders 
 
common Headache 
Thension headache 
Back pain 
Fatigue 
Respiratory disorders common Cough 
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Table 4: Currently ongoing clinical trials testing apremilast in psoriatic patients. 
Study number Study design  Population  Dosing Subjects enrolled 
 
Phase II trials 
 
    
CC-10004-PPSO-001 
[43] 
Multicenter, Open-Label 
Study to Assess the Safety, 
Tolerability and 
Pharmacokinetics of APR  
in Pediatric Subjects  
Pediatric Subjects, male 
and female  with Moderate 
to Severe Plaque Psoriasis 
APR 10 mg b.i.d., 
APR 20 mg b.i.d., 
APR 30 mg b.i.d. 
NA 
CC-10004- PSOR-005 
LTE [42] 
Long-term safety 
extension study for 
subjects 
who completed the 
treatment phase of the 
extension study (CC-
10004-PSOR-005E) 
Male and female subjects 
who 
completed the treatment 
phase of 
the extension study (CC-
10004-PSOR- 
005E) 
APR 20 mg b.i.d., 
APR 30 mg b.i.d. 
56 
Phase III trials 
 
    
CC-10004- 
PSOR-008 
(ESTEEM 1) [5] 
Randomized, double-
blind, placebo-controlled 
study 
Male and female subjects 
with 
moderate-to-severe plaque 
psoriasis 
Placebo, 
APR 30 mg b.i.d. 
844 
CC-10004- 
PSOR-009 
(ESTEEM 2) [44] 
Randomized, double-
blind, placebo-controlled 
study 
Male and female subjects 
with 
moderate-to-severe plaque 
psoriasis 
Placebo, 
APR 30 mg b.i.d. 
413 
CC-10004- 
PSOR-010 
[43] 
Randomized, placebo-
controlled, doubleblind, 
double-dummy study 
Male and female subjects 
with 
moderate-to-severe plaque 
psoriasis 
Placebo tablets + placebo 
injection, 
etanercept 50 mg QW + 
placebo 
tablets, APR 30 mg b.i.d. 
+ placebo 
injection 
250 
Phase IV trials 
 
    
Inno-6040, 
AP-CL- 
PSORCARE- 
005313 
A Double-blind, Placebo-
controlled, 
Randomized Study on the 
Safety and Efficacy 
of APR 
Male and female subjects 
with 
moderate-to-severe plaque 
psoriasis 
involving palms and/or 
soles 
Apremilast, placebo NA 
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AP-CL-PSOR-PI- 
004893 
[43] 
Randomized, 
Safety/Efficacy Study, 
Parallel Assignment, 
Double Blind 
Male and female subjects 
with 
moderate-to-severe plaque 
psoriasis 
Narrowband UVB and 
APR 
NA 
CC-10004- PSOR-012 
[43] 
Multicenter, Randomized, 
Placebo-controlled, 
Double-blind, Study of the 
Efficacy and Safety of 
APR 
Male and female subjects 
with 
moderate-to-severe plaque 
psoriasis 
Apremilast, placebo NA 
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